MoonLake Immunotherapeutics (NASDAQ: MLTX) files Form 144 to report Class A resale intent
Rhea-AI Filing Summary
MoonLake Immunotherapeutics submitted a Form 144 notice concerning proposed sales of Class A common shares. The filing lists a 150,000 share figure alongside account and outstanding figures and shows 3,027,483 shares obtained upon exchange on 10/01/2023.
The filing names UBS Financial Services Inc. as the broker and includes a filing date of 04/10/2026. The excerpt does not state prices, planned sale timing, or proceeds treatment.
Positive
- None.
Negative
- None.
Insights
Form 144 records an intended resale of restricted shares under Rule 144.
This Form 144 lists Class A shares with broker UBS Financial Services Inc. and shows 150,000 in a column alongside account figures; it also records 3,027,483 shares obtained by exchange on 10/01/2023. The notice functions as a seller’s regulatory disclosure rather than an executed sale.
Key dependencies are Rule 144 holding/volume conditions and any broker execution; the excerpt does not show timing, price, or whether volume limitations apply. Subsequent filings or trade reports would show completed transactions.